Yeast-antigen compositions and methods of using the same
View Patent ↗Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a yeast vehicle and an antigen that is not complexed to the yeast vehicle is disclosed.
1. A method to elicit an MHC class I cell-mediated, antigen-specific immune response in a mammal, the method comprising administering to the mammal an immunogenic composition comprising:
a) a yeast vehicle selected from the group consisting of: a whole yeast, a yeast spheroplast, a yeast cytoplast, a yeast ghost, and a subcellular yeast particle, wherein the yeast vehicle is not from Candida ; and,
b) at least one antigen that is heterologous to the yeast vehicle and that is not expressed by or loaded into the yeast vehicle, and that has not been attached to the yeast vehicle;
wherein the composition elicits an MHC class I cell-mediated immune response against the antigen.
2. The method of claim 1 , wherein the immunogenic composition is administered with a pharmaceutically acceptable excipient.
3. The method of claim 1 , wherein the antigen is selected from the group consisting of a viral antigen, a mammalian cell surface molecule, a bacterial antigen, a fungal antigen, a protozoan antigen, a helminth antigen, an ectoparasite antigen, and a cancer antigen.
4. The method of claim 1 , wherein the antigen is a viral antigen.
5. The method of claim 1 , wherein the antigen is a cancer antigen.
6. The method of claim 1 , wherein the antigen is selected from the group consisting of: a protein encoded by HIV-1 gag, a protein encoded by HIV-1 env, a protein encoded by HIV-1 pol, a protein encoded by HIV-1 tat, a protein encoded by HIV-1 nef, HBsAg, HBcAg, hepatitis C core antigen, HPV E6 and E7, HSV glycoprotein D, and Bacillus anthracis protective antigen.
7. The method of claim 1 , wherein the at least one antigen that is heterologous to the yeast vehicle comprises multiple antigens.
8. The method of claim 1 , wherein the antigen is a protein, a fusion protein, a chimeric protein, or an immunogenic fragment thereof.
9. The method of claim 1 , wherein the antigen comprises a T cell epitope capable of presentation by MHC Class I.
10. The method of claim 1 , wherein the composition further comprises at least one biological response modifier.
11. The method of claim 1 , wherein the yeast vehicle is selected from the group consisting of: a whole yeast, a yeast spheroplast, a yeast cytoplast, and a yeast ghost.
12. The method of claim 1 , wherein the yeast vehicle is selected from the group consisting of: a whole yeast and a yeast spheroplast.
13. The method of claim 1 , wherein the yeast vehicle is a whole yeast.
14. The method of claim 1 , wherein the yeast is of a genus selected from the group consisting of Saccharomyces, Cryptococcus, Hansenula, Kluyveromyces, Pichia, Rhodotorula, Schizosaccharomyces and Yarrowia.
15. The method of claim 1 , wherein the yeast vehicle is from Saccharomyces.
16. The method of claim 1 , wherein the yeast vehicle is from a heat-inactivated yeast.
17. The method of claim 1 , wherein the immunogenic composition is administered by a route selected from the group consisting of: intravenous, intraperitoneal, subcutaneous, intradermal, intranodal, intramuscular, transdermal, inhaled, intranasal, oral, intraocular, intraarticular, intracranial, and intraspinal.
18. The method of claim 1 , wherein the immunogenic composition is administered by a route selected from the group consisting of: intraperitoneal and subcutaneous.
19. A method to elicit an MHC class I cell-mediated, antigen-specific immune response in a mammal, the method comprising administering to the mammal an immunogenic composition comprising:
a) a heat-inactivated, whole yeast from Saccharomyces ; and,
b) at least one antigen that is heterologous to the yeast and that is not expressed by or loaded into the yeast, and that has not been attached to the yeast;
wherein the composition elicits an MHC class I cell-mediated immune response against the antigen.
20. The method of claim 19 , wherein the antigen is a protein, a fusion protein, a chimeric protein, or an immunogenic fragment thereof.
21. A method to elicit an MHC class I cell-mediated, antigen-specific immune response in a mammal, the method comprising administering to the mammal an immunogenic composition comprising:
a) a yeast vehicle selected from the group consisting of: a whole yeast, a yeast spheroplast, a yeast cytoplast, a yeast ghost, and a subcellular yeast particle, wherein the yeast vehicle is not from Candida ; and,
b) at least one antigen that is heterologous to the yeast vehicle and that is not expressed by or loaded into the yeast vehicle, and that has not been attached to the yeast vehicle, wherein the antigen is a T cell epitope capable of presentation by MHC class I;
wherein the composition elicits an MHC class I cell-mediated immune response against the antigen.
22. The method of claim 21 , wherein the yeast vehicle is from Saccharomyces.
23. A method to elicit an MHC class I cell-mediated, antigen-specific immune response in a mammal, the method comprising administering to the mammal an immunogenic composition comprising:
a) a whole yeast, wherein the yeast is not from Candida ; and,
b) at least one antigen that is heterologous to the yeast and that is not expressed by or loaded into the yeast, and that has not been attached to the yeast, wherein the antigen is a protein, a fusion protein, a chimeric protein, or an immunogenic fragment thereof;
wherein the composition elicits an MHC class I cell-mediated immune response against the antigen.
24. The method of claim 23 , wherein the yeast vehicle is from Saccharomyces.